Cargando…

The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study

OBJECTIVE: Our aim was to determine if the time interval between bowel resection and initiation of adjuvant chemotherapy impacts survival in advanced ovarian cancers. METHODS: This was a retrospective cohort study using data from two cancer centers, Princess Margaret Cancer Centre in Toronto, Ontari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yoo-Young, Kim, Soyoun Rachel, Kollara, Alexandra, Brown, Theodore, May, Taymaa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634098/ https://www.ncbi.nlm.nih.gov/pubmed/36047378 http://dx.doi.org/10.3802/jgo.2022.33.e76

Ejemplares similares

A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
por: Clark, Mitchell, et al.
Publicado: (2021)

Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model
por: Lee, Yooyoung, et al.
Publicado: (2018)

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
por: McNamara, Blair, et al.
Publicado: (2021)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial
por: Lim, Myong Cheol, et al.
Publicado: (2022)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
por: Marchocki, Zibi, et al.
Publicado: (2022)

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
por: Miralpeix, Ester, et al.
Publicado: (2022)

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer
por: Luna-Abanto, Jorge, et al.
Publicado: (2020)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
por: Johnson, Racheal Louise, et al.
Publicado: (2021)

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study
por: Carbajal-Mamani, Semiramis L., et al.
Publicado: (2020)

Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study
por: Llueca, Antoni, et al.
Publicado: (2023)

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer
por: Ferrandina, G, et al.
Publicado: (1999)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study
por: Macrì, Antonio, et al.
Publicado: (2020)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
por: Piso, Pompiliu, et al.
Publicado: (2004)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC
por: Sluiter, Nina R., et al.
Publicado: (2018)

A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer
por: BATISTA, THALES PAULO, et al.
Publicado: (2022)

Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery
por: McCool, Kevin W, et al.
Publicado: (2018)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
por: Jiang, Caixia, et al.
Publicado: (2021)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
por: van de Laar, Rafli, et al.
Publicado: (2014)

Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses
por: Souadka, Amine, et al.
Publicado: (2022)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
por: Dhiman, Pravesh, et al.
Publicado: (2022)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
por: Dhiman, Pravesh, et al.
Publicado: (2022)

Early results on the use of biomaterials as adjuvant to abdominal wall closure following cytoreduction and hyperthermic intraperitoneal chemotherapy
por: Boutros, Cherif, et al.
Publicado: (2010)

Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases
por: Di Giorgio, Angelo, et al.
Publicado: (2016)

Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction
por: Cummings, Mackenzie, et al.
Publicado: (2022)

Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity
por: Kollara, Alexandra, et al.
Publicado: (2012)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

En-bloc rectosigmoid and mesorectum resection as part of pelvic cytoreductive surgery in advanced ovarian cancer
por: Alcazar, Juan Luis, et al.
Publicado: (2020)

Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
por: Di Donato, Violante, et al.
Publicado: (2020)

Hepatic Hilar Lymph Node Resection in Cytoreductive Surgery for Advanced Ovarian Cancer: A Necessity or Not?
por: Huang, Honglian, et al.
Publicado: (2021)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018)

Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
por: Tentes, Antonios-Apostolos K., et al.
Publicado: (2012)

Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7q0rinhtjoclv2jd2ba0b0riv0